Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Trial Profile

An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2019

At a glance

  • Drugs Pasireotide (Primary) ; Cabergoline
  • Indications Carcinoid tumour; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2019 Pasireotide may be given either alone or in combination with Cabergoline (another treatment for Cushing's Disease and Acromegaly ), number of arm chaned from 1 to 2 and number of patients changed form 400 to 500.
    • 07 Jul 2019 Planned number of patients changed from 400 to 500.
    • 07 Jul 2019 Planned End Date changed from 12 Jun 2023 to 9 Jun 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top